Gilead Sciences stock (US3755581036): shares steady as ASCO oncology focus highlights pipeline

Gilead Sciences stock traded near USD 134.00 on Nasdaq under the ticker GILD on 05/31/2026, with the latest quote showing the shares roughly flat on the day and sitting between a 05/31/2026 intraday low of USD 133.46 and a high of USD 137.20, according to Robinhood data as of 05/31/2026.Robinhood as of 05/31/2026

The move keeps the United States-based biotech group’s market capitalization around USD 167 billion, with a stated price/earnings ratio of about 18.3 and a dividend yield close to 2.4 percent on 05/31/2026, underscoring Gilead’s position as a major Nasdaq-listed pharmaceutical name.Robinhood as of 05/31/2026

Trading volume reached roughly 17.5 million shares versus an average daily volume near 6.8 million on 05/31/2026, indicating elevated activity in the home US market even as the price itself has been comparatively stable in the latest session.Robinhood as of 05/31/2026

For German investors following the name in Europe, Gilead is also available in euros on venues such as Tradegate and Frankfurt, but the primary listing and price discovery remain centered on Nasdaq in the United States.

In parallel to the share price picture, Gilead continues to attract attention around the American Society of Clinical Oncology (ASCO) 2026 meeting, where the company’s leadership has been discussing advances in cell therapies and antibody-drug conjugate strategies in oncology.BiotechTV as of 05/30/2026

As of: 05/31/2026

By the editorial team - specialized in equity coverage.

Gilead Sciences: core business model

Gilead Sciences focuses on developing and commercializing specialized antiviral and oncology medicines, with revenue largely tied to branded therapies for HIV, hepatitis and cancer that are marketed across major global healthcare systems.

Chart technicals and 52-week range

From a technical standpoint, Gilead’s Nasdaq-quoted shares have oscillated within an approximate 52-week corridor centered in the low to mid-USD 100 range, with the 05/31/2026 mark around USD 134.00 positioning the stock nearer the middle of that broad band based on Robinhood’s historical chart data.Robinhood as of 05/31/2026

Short-term indicators from broker chart tools place the latest price modestly above the recent low of USD 133.46 on 05/31/2026 and a few percentage points below the same-day intraday high of USD 137.20, suggesting that, despite the increased trading volume, the share has stayed within a relatively narrow intraday range rather than marking a decisive breakout.Robinhood as of 05/31/2026

Conclusion

The latest session on 05/31/2026 leaves Gilead Sciences shares trading close to USD 134 on Nasdaq, with higher-than-average volume signaling active interest but no sharp move in either direction. Against this calm price backdrop, the spotlight at ASCO 2026 on Gilead’s cell therapy and antibody-drug conjugate efforts underlines how much of the medium-term story is tied to oncology innovation rather than short-term trading swings. For investors tracking the stock, the interaction between these technical levels and future clinical and regulatory milestones in the home United States market is likely to remain a central theme.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.